# Christopher F. Bell

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/christopher-f-bell/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,729 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 22 |
| i10-index | 38 |
| Last Known Institution | Family Health International 360 |
| OpenAlex ID | https://openalex.org/A5077494238 |
| ORCID iD | 0000-0001-6413-2537 |
| Works | 93 |

## Researcher papers

Showing 12 of 15.

- [The burden of Duchenne muscular dystrophy](https://scholariq.org/papers/the-burden-of-duchenne-muscular-dystrophy/)
- [Quantifying the burden of caregiving in Duchenne muscular dystrophy](https://scholariq.org/papers/quantifying-the-burden-of-caregiving-in-duchenne-muscular-dystrophy/)
- [Health‐related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross‐sectional study](https://scholariq.org/papers/health-related-quality-of-life-in-patients-with-duchenne-muscular-dystrophy-a/)
- [Cost-effectiveness of Four Immunomodulatory Therapies for Relapsing-Remitting Multiple Sclerosis: A Markov Model Based on Long-term Clinical Data](https://scholariq.org/papers/cost-effectiveness-of-four-immunomodulatory-therapies-for-relapsing-remitting/)
- [Compliance to Care Guidelines for Duchenne Muscular Dystrophy](https://scholariq.org/papers/compliance-to-care-guidelines-for-duchenne-muscular-dystrophy/)
- [Treating Early Versus Treating Mild: Timing of Migraine Prescription Medications Among Patients With Diagnosed Migraine](https://scholariq.org/papers/treating-early-versus-treating-mild-timing-of-migraine-prescription-medications/)
- [A Randomized, Controlled Trial of Gabapentin Enacarbil in Subjects with Neuropathic Pain Associated with Diabetic Peripheral Neuropathy](https://scholariq.org/papers/a-randomized-controlled-trial-of-gabapentin-enacarbil-in-subjects-with/)
- [&lt;p&gt;Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs&lt;/p&gt;](https://scholariq.org/papers/and-lt-p-and-gt-real-world-effectiveness-of-mepolizumab-in-patients-with-severe/)
- [Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States](https://scholariq.org/papers/results-of-an-economic-model-to-assess-the-cost-effectiveness-of-enoxaparin-a/)
- [Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA](https://scholariq.org/papers/real-world-effectiveness-of-sotrovimab-for-the-early-treatment-of-covid-19/)
- [The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States](https://scholariq.org/papers/the-cost-of-flares-among-patients-with-systemic-lupus-erythematosus-with-and/)
- [Clinical and Economic Burden of Systemic Lupus Erythematosus in the Years Preceding End-Stage Kidney Disease Diagnosis: A Retrospective Observational Study](https://scholariq.org/papers/clinical-and-economic-burden-of-systemic-lupus-erythematosus-in-the-years/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [SARS-CoV-2 and COVID-19 Research](https://scholariq.org/topics/sars-cov-2-and-covid-19-research/)
- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)

## Researcher university

- [Family Health International 360](https://scholariq.org/institutions/family-health-international-360/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.
